XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Note 14 - Distribution Agreements | 6 Months Ended
--- | ---
Jun. 30, 2024
Notes to Financial Statements |
License, Collaboration, and Distribution Agreements [Text Block] | NOTE 14. DISTRIBUTION AGREEMENTS Transactions under the Company’s major distribution agreements are recognized upon transfer of control of products sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. Product Sales Discounts and Allowances The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the six months ended June 30, 2024 (in thousands):
|  | Chargebacks, Discounts for Prompt Payment |  |  | Other Customer Fees |  |  | Rebates |  |  | Total |
Balance at December 31, 2023 |  | $ | 913 |  |  | $ | 12 |  |  | $ | 21 |  |  | $ | 946 |
Less discontinued operations |  |  | (218 | ) |  |  | — |  |  |  | — |  |  |  | (218 | )
Continuing operations balance at December 31, 2023 |  |  | 695 |  |  |  | 12 |  |  |  | 21 |  |  |  | 728 |
Provision related to sales made in: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Current period |  |  | 57 |  |  |  | 23 |  |  |  | 52 |  |  |  | 132 |
Payments and customer credits issued |  |  | (11 | ) |  |  | (22 | ) |  |  | (54 | ) |  |  | (87 | )
Balance at June 30, 2024 |  | $ | 741 |  |  | $ | 13 |  |  | $ | 19 |  |  | $ | 773 |
Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. The Company has also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three months ended June 30, 2024 and 2023, the Company earned $108 thousand and $195 thousand, respectively, in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements. During the six months ended June 30, 2024 and 2023, the Company earned $232 thousand and $287 thousand, respectively, in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements. Under these product distribution arrangements, the Company had a contract liability balance of $0.8 million and $0.7 million as of June 30, 2024 and December 31, 2023, respectively. The contract liability is included in accrued liabilities in the condensed consolidated balance sheets. Over-the-Counter Sales of Avenova Spray Avenova Spray is offered for sale direct to U.S. customers primarily on Amazon.com, the Company’s website (Avenova.com) and Walmart.com. During the three months ended June 30, 2024 and 2023, the revenue generated from Avenova Spray in these channels was $1.8 million and $1.3 million, respectively. During the six months ended June 30, 2024 and 2023, the revenue generated from Avenova Spray in these channels was $3.5 million and $2.9 million, respectively.

X
- Definition The entire disclosure of license, collaboration, and distribution agreements. + References No definition available. + Details
Name: | nby_LicenseCollaborationAndDistributionAgreementsTextBlock
Namespace Prefix: | nby_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration